Quanterix Q1 revenue $36.4M (+20% YoY); reaffirms FY2026 guidance of $169-174M

Quanterix Corp

2026-Q1 EPS reported -$0.37 vs consensus -$0.55 ▲ beat (+33.2%)

Revenue of $36.4M, up 20% YoY; GAAP gross margin 42.7%, adjusted 50.9%.
Adjusted EBITDA loss $9.8M, improved from $11.3M loss a year ago.
Cash and marketable securities $102.6M; targeting cash flow breakeven in H2 2026.
Alzheimer's diagnostics business growing; 510(k) filing with FDA expected in H2 2026.
Collaborations with Tempus AI and Life Line Screening for blood-based biomarker tests.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Quanterix Corp reported the first quarter ended March 31, 2026 results: revenue $36.4 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $36.4 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Quanterix Releases Financial Results for the First Quarter of 2026 Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness

View on SEC.gov

Browse all earnings releases →

Quanterix Corp filing history →

Source: SEC EDGAR

accession 0001503274-26-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.